AFP and hepatocellular carcinoma: Current HCC surveillance primarily relies on ultrasound and AFP [28], but emerging evidence in Thailand, the United Kingdom and China supports the incremental integration of novel biomarkers such as PIVKA-II and digital algorithms like GAAD, which are cost-effective and improve early detection [65,71,72].